Target FGF23, the underlying cause of chronic hypophosphatemia in TIO
CRYSVITA® (burosumab-twza) is the first and only FDA-approved therapy targeting excess fibroblast growth factor 23 (FGF23) in patients with tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
CRYSVITA for TIO